Cyclerion Therapeutics (NASDAQ:CYCN) Trading 0.6% Higher – Here’s What Happened
by Mitch Edgeman · The Markets DailyCyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report) was up 0.6% on Monday . The company traded as high as $3.28 and last traded at $3.22. Approximately 20,180 shares traded hands during trading, a decline of 29% from the average daily volume of 28,300 shares. The stock had previously closed at $3.20.
Analysts Set New Price Targets
Separately, Weiss Ratings upgraded shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, April 29th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.
View Our Latest Report on CYCN
Cyclerion Therapeutics Trading Up 0.6%
The company has a fifty day moving average of $3.10 and a 200-day moving average of $2.18. The stock has a market cap of $13.94 million, a PE ratio of -2.37 and a beta of 1.79.
Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.76) earnings per share for the quarter, beating the consensus estimate of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. As a group, research analysts anticipate that Cyclerion Therapeutics, Inc. will post -1.2 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cyclerion Therapeutics
An institutional investor recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new stake in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned approximately 0.40% of Cyclerion Therapeutics at the end of the most recent quarter. Institutional investors own 75.62% of the company’s stock.
About Cyclerion Therapeutics
Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.
The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.